An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
Public ClinicalTrials.gov record NCT02783651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Observational Study of Patients With Philadelphia Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
Study identification
- NCT ID
- NCT02783651
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 212 participants
Conditions and interventions
Interventions
- Other Other
Other
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2016
- Primary completion
- Mar 30, 2020
- Completion
- Mar 30, 2020
- Last update posted
- Apr 26, 2020
2016 – 2020
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85719 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Los Angeles | California | 90089 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Ames | Iowa | 50010 | — |
| Research Site | New Orleans | Louisiana | 70112 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Hackensack | New Jersey | 07601 | — |
| Research Site | Buffalo | New York | 14263 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Cincinnati | Ohio | 45229 | — |
| Research Site | Cleveland | Ohio | 44106 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Austin | Texas | 78701 | — |
| Research Site | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02783651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2020 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02783651 live on ClinicalTrials.gov.